Company intelligence / Profile preview

OmnigenicsAI

Grand Cayman, Cayman Islands

Ownership: Private
Development stage: Other

Overview

OmnigenicsAI is a commercial-stage AI-driven genomics company focused on precision medicine and diagnostics. It resulted from a business combination involving APx Acquisition Corp. I (a SPAC), OmnigenicsAI Corp (formerly Heritas), and MultiplAI Health Ltd. The company utilizes a proprietary AI platform for RNA genomic sequencing, data transformation, and comprehensive analysis, offering services in prevention, early detection, and diagnostics for conditions like cardiovascular disease, oncology, and rare diseases. The company aims to go public on NASDAQ in mid-2024.

Therapeutic areas: OncologyCardiovascularRare Diseases
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on OmnigenicsAI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OmnigenicsAI.

Explore the full profile